Cosmos Health Enters U.S. Market with Strategic Manufacturing Deal with DolCas Biotech

Reuters

06-24

Cosmos Health Enters U.S. Market with Strategic Manufacturing Deal with DolCas Biotech

Cosmos Health Inc. has announced its strategic entry into the U.S. market through a new manufacturing agreement with DolCas Biotech LLC, a New Jersey-based developer of nutraceutical ingredients. This collaboration marks a significant milestone for Cosmos Health as it begins U.S.-based production at GMP-certified facilities, enhancing its control over production processes and reducing risks associated with tariffs and cross-border logistics. The agreement with DolCas Biotech not only strengthens Cosmos Health's position in the premium nutraceuticals market but also supports its broader strategy of expanding its portfolio with scientifically backed ingredients. This partnership is seen as a key step in Cosmos Health's global growth strategy, under the leadership of CEO Greg Siokas, and aims to leverage DolCas's expertise in innovative, clinically validated formulations.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cosmos Health Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9483638-en) on June 24, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2545364002"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2545364002\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2545364002?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-24 22:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2545364002","market":"nz","top_or_hot":-1,"title":"Cosmos Health Enters U.S. Market with Strategic Manufacturing Deal with DolCas Biotech","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Cosmos Health Enters U.S. Market with Strategic Manufacturing Deal with DolCas Biotech\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Cosmos Health Inc. has announced its strategic entry into the U.S. market through a new manufacturing agreement with DolCas Biotech LLC, a New Jersey-based developer of nutraceutical ingredients. This collaboration marks a significant milestone for Cosmos Health as it begins U.S.-based production at GMP-certified facilities, enhancing its control over production processes and reducing risks associated with tariffs and cross-border logistics. The agreement with DolCas Biotech not only strengthens Cosmos Health's position in the premium nutraceuticals market but also supports its broader strategy of expanding its portfolio with scientifically backed ingredients. This partnership is seen as a key step in Cosmos Health's global growth strategy, under the leadership of CEO Greg Siokas, and aims to leverage DolCas's expertise in innovative, clinically validated formulations.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cosmos Health Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9483638-en) on June 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cosmos Health Enters U.S. Market with Strategic Manufacturing Deal with DolCas Biotech</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCosmos Health Enters U.S. Market with Strategic Manufacturing Deal with DolCas Biotech\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-06-24 22:55</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Cosmos Health Enters U.S. Market with Strategic Manufacturing Deal with DolCas Biotech\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Cosmos Health Inc. has announced its strategic entry into the U.S. market through a new manufacturing agreement with DolCas Biotech LLC, a New Jersey-based developer of nutraceutical ingredients. This collaboration marks a significant milestone for Cosmos Health as it begins U.S.-based production at GMP-certified facilities, enhancing its control over production processes and reducing risks associated with tariffs and cross-border logistics. The agreement with DolCas Biotech not only strengthens Cosmos Health's position in the premium nutraceuticals market but also supports its broader strategy of expanding its portfolio with scientifically backed ingredients. This partnership is seen as a key step in Cosmos Health's global growth strategy, under the leadership of CEO Greg Siokas, and aims to leverage DolCas's expertise in innovative, clinically validated formulations.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cosmos Health Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9483638-en) on June 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2095319765.USD","symbol_name":"Natixis Thematics Subscription Economy R/A USD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250624:nNDLbgNJpv:1","article_id":"2545364002","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2545364002","pubTimestamp":1750776945,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Cosmos Health Inc. has announced its strategic entry into the U.S. market through a new manufacturing agreement with DolCas Biotech LLC, a New Jersey-based developer of nutraceutical ingredients. This collaboration marks a significant milestone for Cosmos Health as it begins U.S.-based production at GMP-certified facilities, enhancing its control over production processes and reducing risks associated with tariffs and cross-border logistics. The agreement with DolCas Biotech not only strengthens Cosmos Health's position in the premium nutraceuticals market but also supports its broader strategy of expanding its portfolio with scientifically backed ingredients. This partnership is seen as a key step in Cosmos Health's global growth strategy, under the leadership of CEO Greg Siokas, and aims to leverage DolCas's expertise in innovative, clinically validated formulations.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT st","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4588":"碎股","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","NDAQ":"纳斯达克OMX交易所","COSM":"COSMOS HEALTH INC","BK4585":"ETF&股票定投概念","BK4175":"保健护理产品经销商","BK4112":"金融交易所和数据","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC"},"translate_title":"宇宙健康进入美国。与DolCas Biotech达成战略制造协议的市场","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"COSM":0.9,"NDAQ":0.9},"content_text":"Cosmos Health Enters U.S. Market with Strategic Manufacturing Deal with DolCas Biotech\n    \n\n        Cosmos Health Inc. has announced its strategic entry into the U.S. market through a new manufacturing agreement with DolCas Biotech LLC, a New Jersey-based developer of nutraceutical ingredients. This collaboration marks a significant milestone for Cosmos Health as it begins U.S.-based production at GMP-certified facilities, enhancing its control over production processes and reducing risks associated with tariffs and cross-border logistics. The agreement with DolCas Biotech not only strengthens Cosmos Health's position in the premium nutraceuticals market but also supports its broader strategy of expanding its portfolio with scientifically backed ingredients. This partnership is seen as a key step in Cosmos Health's global growth strategy, under the leadership of CEO Greg Siokas, and aims to leverage DolCas's expertise in innovative, clinically validated formulations.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cosmos Health Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9483638-en) on June 24, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}